TECVAYLI® and DARZALEX FASPRO®-based induction treatment demonstrates promising rates and depths of response in transplant-eligible patients with newly diagnosed multiple myeloma

Core Insights - Johnson & Johnson announced that 100 percent of evaluable patients achieved minimal residual disease (MRD) negativity following induction therapy in the Phase 2 MajesTEC-5 study [1] Company Summary - The investigational immune-based induction regimen includes TECVAYLI® (teclistamab-cqyv) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) [1] - The study demonstrated meaningful clinical efficacy in transplant-eligible patients with newly diagnosed multiple myeloma [1]